Masimo

Masimo's mission is to improve patient outcomes and reduce the cost of care by innovating in non-invasive monitoring. The company achieved global leadership through its clinically superior SET® pulse oximetry platform and has since diversified into multi-parameter monitoring and hospital automation. Its current strategy focuses on expanding into new care settings (home, wearables) and leveraging its 2022 acquisition of Sound United to fuse consumer audio with health sensing technology.

Signal Extraction Technology (SET®) uses parallel engines and adaptive filtering to isolate arterial signals from noise, enabling accurate non-invasive monitoring. The rainbow® platform expands this to multi-parameter Pulse CO-Oximetry, measuring hemoglobin, carboxyhemoglobin, methemoglobin, and more.

Masimo faces competition from large, diversified medtech giants (Medtronic, Philips, GE), specialist sensor companies, and disruptive tech entrants like Apple. Its defensible moat is its clinically superior SET® and rainbow® technology and a robust IP portfolio, but it must navigate bundling pressure from larger rivals and execution of its novel consumer audio-health strategy.